| Title |
A cohort study of exposure to antihyperglycemic therapy and survival in patients with lung cancer |
| Authors |
Danila, Edvardas ; Linkevičiūtė-Ulinskienė, Donata ; Zablockis, Rolandas ; Gruslys, Vygantas ; Cicėnas, Saulius ; Smailytė, Giedrė |
| DOI |
10.3390/ijerph17051747 |
| Full Text |
|
| Is Part of |
International journal of environmental research and public health.. Basel : MDPI AG. 2020, vol. 17, no. 5, p. [1-12].. ISSN 1661-7827. eISSN 1660-4601 |
| Keywords [eng] |
diabetes ; insulin ; lung cancer ; metformin |
| Abstract [eng] |
We evaluated the effect of antihyperglycemic therapy on the survival of patients with lung cancer (LC). The analysis included patients with LC and concomitant type 2 diabetes. 15,929 patients were classified into five groups: metformin users, insulin users, metformin and insulin users, sulphonylurea users and non-diabetic group. A multivariate analysis showed that exposure to either metformin or to insulin was associated with a lower risk of LC-specific mortality, and this approached statistical significance (HR 0.82, 95% CI 0.72-92 for metformin and HR 0.65, 95% CI 0.44-95 for insulin). When deaths from all causes were considered, only metformin exposure was associated with a significantly lower risk of death (HR 0.82, 95% CI 0.73-0.92). Users of sulphonylurea were at a higher risk of LC-specific and overall mortality (HRs 1.19, 95% CI 0.99-1.43 and 1.22, 95% CI 1.03-1.45). Our study shows a positive effect of metformin on the survival of patients with LC. Moreover, our results show that exposure to insulin was associated with a lower risk of LC-specific mortality, but not with deaths from all causes. The study results suggested that users of sulphonylurea may be at a higher risk of LC-specific and overall mortality. |
| Published |
Basel : MDPI AG |
| Type |
Journal article |
| Language |
English |
| Publication date |
2020 |
| CC license |
|
